Insulet, headquartered in Acton, Massachusetts, develops and markets insulin infusion systems, including the Omnipod 5 Automated Insulin Delivery System, for insulin-dependent diabetes. The company employs 3,000 staff and went public in 2007.
PODD has been in the news recently: Insulet Corp. (NASDAQ:PODD) shares experienced a decline in premarket trading following the announcement of a voluntary Medical Device Correction for some Omnipod 5 Pods. This correction may impact consumer confidence in Insulet's products and influence its stock performance.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.